Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 9/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 8/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20627702 | 0.91 | KDM4E (0.40) | KDM4ENPC1RAB9ASMN1; SMN2GSK3B | |
| SCHEMBL17182959 | 0.89 | KDM4E (0.53) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17182911 | 0.82 | KDM4E (0.57) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL20627581 | 0.82 | KDM4E (0.45) | KDM4ENPC1RAB9ASMN1; SMN2GSK3B | |
| SCHEMBL17182839 | 0.79 | GSK3B (0.39) | KDM4ENPC1RAB9ASMN1; SMN2GSK3B | |
| SCHEMBL16720804 | 0.78 | GSK3B (0.44) | GSK3BCDK2MAPKAPK2 | |
| SCHEMBL17182908 | 0.77 | CDK2 (0.44) | GSK3BCDK2 | |
| SCHEMBL15718407 | 0.76 | PDE4D (0.42) | GSK3BCDK2 | |
| SCHEMBL20627807 | 0.76 | GSK3B (0.43) | KDM4EGSK3BMAPTCDK2 | |
| SCHEMBL17182829 | 0.75 | GSK3B (0.44) | KDM4ENPC1RAB9ASMN1; SMN2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570143-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2020-02-25 | — | — | US | disclosed |
| US-10570143-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2020-02-25 | — | — | US | disclosed |
| US-20190040074-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2019-02-07 | — | — | US | disclosed |
| US-20190040074-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2019-02-07 | — | — | US | disclosed |
| EP-2920181-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIV HEALTH NETWORK (CA) | 2019-01-09 | — | — | EP | disclosed |
| US-10106545-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2018-10-23 | — | — | US | disclosed |
| US-20170217966-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170217966-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170217966-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9573954-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-21 | — | — | US | disclosed |
| US-9573954-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-21 | — | — | US | disclosed |
| US-9573954-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-21 | — | — | US | disclosed |
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | KDM4E 2089/4885NPC1 487/4885RAB9A 1263/4885 |
| US-10570143-B2 | Pyrazolopyrimidine compounds | CYP3A5, CYP3A7, DPYD | KDM4E 2089/4885NPC1 487/4885RAB9A 1263/4885 |
| US-10106545-B2 | Pyrazolopyrimidine compounds | CYP3A5, CYP3A7, DPYD | KDM4E 2636/4885NPC1 710/4885RAB9A 1169/4885 |
| US-20170217966-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | KDM4E 2636/4885NPC1 710/4885RAB9A 1169/4885 |
| US-20190040074-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | KDM4E 2636/4885NPC1 710/4885RAB9A 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.